CREATE Medicines Rebrand From Myeloid Therapeutics Reflects Strategic Expansion into Multi-Lineage RNA Immunotherapy as Europe’s Biotech Sector Embraces In Vivo Therapies

Rebranded CREATE Medicines Positions Itself at the Forefront of RNA Immunotherapy as Europe’s Biotech Ecosystem Accelerates Innovation

• Rebrand: Myeloid Therapeutics becomes CREATE Medicines, reflecting a shift to multi-lineage RNA immune programming.
• Scientific Focus: Expanding beyond myeloid cells to include T and NK cells for scalable, redosable in vivo CAR therapies.
• Clinical Data: Over 40 patients treated with confirmed immune cell reprogramming and solid safety profile.
• Pipeline: Advancing HER2, TROP2, and GPC3 programs plus the first RNA retrotransposon-based in vivo CAR-T for B-cell depletion.
• Core Technology: Proprietary mRNA-LNP platform enables direct immune cell programming inside the body.
• Investment: Backed by ARCH Venture Partners, Newpath Partners, 8VC, and Hatteras Venture Partners.
• European Context: Rebrand aligns with Europe’s growing focus on RNA therapeutics and in vivo immunotherapy.

(NEWS) CAMBRIDGE, MA, United States, 7-Oct-2025 — /EuropaWire/ — In a strategic pivot and rebrand, Myeloid Therapeutics has relaunched as CREATE Medicines, according to the company’s announcement made on EuropaWire on 6 Oct. 2025, broadening its initial myeloid-only immunotherapy focus into a new era of multi-lineage RNA-based in vivo programming—targeting not just myeloid cells but also T cells and NK cells—to deliver scalable, repeatable off-the-shelf CAR (chimeric antigen receptor) therapies for cancer, autoimmunity, and fibrosis.

Since its earliest trials, the company has treated over 40 patients and delivered more than 200 doses with a consistent safety profile, confirming in vivo reprogramming of immune cells and signs of antitumor activity. Its pipeline now includes MT-302 (TROP2), MT-303 (GPC3), and MT-304 (HER2, soon to initiate in Q4 2025)—the latter being its first multi-immune CAR engaging NK and myeloid cells—and a novel RNA retrotransposon–based in vivo CAR-T for permanent B-cell depletion.

The renaming from Myeloid Therapeutics to CREATE Medicines aligns with this scientific and strategic evolution: “Myeloid” had emphasized a narrow cell lineage, while “CREATE” signals ambition to design and build therapies across multiple immune arms. It underscores a shift from a specialized niche toward a broader immunotherapy identity.

At its core, CREATE Medicines’ core competence lies in its proprietary mRNA–lipid nanoparticle (LNP) delivery platform that programs immune cells in vivo (i.e. within the patient). The company can deliver transient or stable CAR expression and even permanent CAR integration via RNA-based retrotransposon tools—all while maintaining control, scalability, repeat dosing, and manageable safety. Its market is essentially next-generation immunotherapy: CAR-based therapies delivered directly in the body rather than via ex vivo manipulation.

European Market Context & Opportunity

In Europe, the mRNA therapeutics market is projected to grow strongly, reaching an estimated value of USD 3,348.9 million in 2023 and expanding at a CAGR of ~14.6 % through 2030, according to Grand View Research. Contract development and manufacturing (CDMO) for mRNA therapies in Europe is also on the rise, with forecasts suggesting the European CDMO sector could reach USD 2,336.2 million by 2030, growing at ~15.3 % annually.

Moreover, Europe is now becoming a more active ground for in vivo CAR trials: a U.S.-based in vivo CAR therapeutic recently expanded into Germany under regulatory approval—marking the first of its kind in Europe, according to  Labiotech.eu. 

For CREATE Medicines, the European landscape offers both challenges and opportunity. Regulatory standards in the EU are high, but the region is increasingly receptive to RNA-based innovation and strong public health infrastructure could support adoption. Access to European CDMO capacity, growing local investment in RNA and cell therapy, and regulatory precedent for in vivo CAR trials all form a favourable backdrop. If CREATE can gain European trial traction and manufacturing scale, it could tap into a fast-growing, well-funded ecosystem keen on next-generation immunotherapies.